
Hepatitis C: State of Medicaid Access Report Card

Wyoming



Grade	Recommendations to Improve Patient Access		
C	 Remove prior authorization for HCV treatment. Remove drug screening requirement. Remove limit of one course of treatment per lifetime. Remove additional restrictions as described below. 		

State Overview

As of February 2022, 73,028 individuals were enrolled in Medicaid and CHIP.¹ It is estimated that as of 2016, 3,700 people were living with HCV in Wyoming.² All Medicaid beneficiaries receive care through the Fee-For-Service (FFS) program. Wyoming does not contract with any Managed Care Organizations (MCOs).³ Thus, Hepatitis C coverage requirements are uniform through the program.

The Wyoming Medicaid Preferred Drug List includes Mavyret and Sofosbuvir/Velpatasvir.4

Deductions		Policy		
Prior Authorization	-8	Prior authorization is required for all HCV treatment regimens. ⁵		
Fibrosis Restrictions		Wyoming Medicaid does not impose fibrosis restrictions. ⁶		
Substance Use Restrictions	-4	Wyoming Medicaid imposes substance use restrictions. Wyoming requires drug screening within 30 days of treatment and may require additional information prior to authorization in the case of a positive test for illicit drugs. ⁷		
Prescriber Restrictions		Wyoming Medicaid does not impose prescriber restrictions.8		
Retreatment Restrictions	-8	Wyoming Medicaid imposes retreatment restrictions. Wyoming allows only one course of treatment per lifetime. ⁹		
Access in Managed Care		Wyoming does not contract with MCOs. ¹⁰		
Additional Restrictions	-4	 Wyoming Medicaid imposes additional restrictions as follows:¹¹ Documentation of HCV genotype. Wyoming Medicaid requires the prescriber to document patient's ability to adhere to treatment via a psychosocial readiness survey. Additionally, Wyoming penalizes poor adherence to treatment: "Non-compliance with the prescribed Hepatitis C regimen may put the client in jeopardy for denial of coverage in the future." ¹² 		
Total Deductions -24		Total Score [100-Deductions] 76	Grade C	

Contact Your State Officials

Medicaid Office: Mailing Address: Wyoming Department of Health, 3001 E. Pershing Blvd., Suite 125, Cheyenne, WY 82001; Phone Number: 1-855-294-2127





Pharmacy & Therapeutics Committee: Mailing Address: Wyoming Drug Utilization Review (WY-DUR), Dept. 3375, 1000 E. University Ave., Laramie, WY 82071; Phone: 307-766-6750; Email: alewis13@uwyo.edu.

Key Sources

Preferred Drug List: Wyoming Medicaid, PDL (Apr. 11, 2022)

Clinical Criteria: Wyoming Medicaid does not publish clinical criteria.

Prior Authorization Form: Wyoming Medicaid, Prior Authorization Form and Patient Commitment Form

¹ CMS, Medicaid & Chip in Wyoming, https://perma.cc/9077-N6QL.

² HepVu, Local Data: Wyoming, https://perma.cc/DLR3-QFJ8.

³ Kaiser Family Foundation, Share of Medicaid Population Covered Under Different Delivery Systems (Jul. 1, 2021), https://perma.cc/993X-QJXS.

⁴ Preferred Drug List.

⁵ Preferred Drug List.

⁶ Prior Authorization Form.

⁷ Prior Authorization Form.

⁸ Prior Authorization Form.

⁹ Prior Authorization Form.

¹⁰ KFF, Share of Medicaid Population Covered under Different Delivery Systems (Jul. 2021): https://perma.cc/6TNW-S2DB.

¹¹ Prior Authorization Form.

¹² Prior Authorization Form.

¹³ Wyoming Department of Health, Apply for Medicaid: https://perma.cc/JJS8-M2HE.

¹⁴ Wyoming Drug Utilization Review, P&T Committee Past Meeting Minutes: https://perma.cc/WE8B-JEW6.